First Quadrant’s Regeneron Pharmaceuticals REGN Stock Holding History

First Quadrant’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-508	Closed	-$321K	–	442
2021 Q4	$321K	Buy	+508	New	+$312K	0.03%	291
2020 Q3	–	Sell	-134	Closed	-$84K	–	700
2020 Q2	$84K	Buy	+134	New	+$76.1K	0.01%	592

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Quadrant's REGN Position: Q1 2022 in Review

First Quadrant sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 508 shares — an estimated $321K sold.

First Quadrant first reported a position in REGN in Q2 2020 and held it in 2 quarters. The position peaked at $321K in Q4 2021. 1,094 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

First Quadrant reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
First Quadrant sold 508 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $321K.
First Quadrant first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 2 quarters.
First Quadrant's Regeneron Pharmaceuticals position peaked at $321K in Q4 2021.
1,094 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.